NCT03111654

Brief Summary

Atrial fibrillation (AF) is a frequent heart rhythm disorder, responsible for the formation of cardiac thrombi, which can embolize in the systemic circulation, responsible for strokes (Cerebrovascular accidents). AF increases the risk of stroke and stroke-related disability. Preventing the thromboembolic risk associated with FMD is therefore a public health issue. The reference treatment is oral anticoagulation but this treatment is contraindicated in patients with a history of intracranial hemorrhage. The percutaneous closure of the auricle is a recent technique which makes it possible to exclude this appendix from the left atrium where the majority of thrombi are formed in the framework of the AF. Comparative studies have shown the effectiveness of this technique, appearing to be similar to that of anticoagulation. However, in view of the per-procedural risk, the indication of closure was retained by the health authorities only in the event of a contraindication to oral anticoagulants in patients with non-valvular AF with a high thromboembolic risk. Patients with a history of intracranial hemorrhage are therefore candidates for this technique, but there are few studies where these patients were included. The risk-benefit must be demonstrated over the long term, in terms of ischemic, hemorrhagic recurrence and becoming functional and cognitive.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for not_applicable atrial-fibrillation

Timeline
Completed

Started Jul 2016

Shorter than P25 for not_applicable atrial-fibrillation

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 14, 2016

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

April 7, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

April 13, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 19, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 19, 2017

Completed
Last Updated

November 19, 2025

Status Verified

November 1, 2025

Enrollment Period

1.3 years

First QC Date

April 7, 2017

Last Update Submit

November 17, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Compare the risk of vascular event (ischemic stroke, haemorrhagic stroke, systemic embolism or cardiovascular or indeterminate death) in patients treated at the Amiens University Hospital with a history of AF and intracranial haemorrhage

    1 hours

Study Arms (2)

Patients with pericardial closure of the auricle

OTHER
Diagnostic Test: Compare the risk of a vascular event

Patients without closure of the auricle

OTHER
Diagnostic Test: Compare the risk of a vascular event

Interventions

Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales. Analysis of selected therapeutic options for the prevention of AF ischemic events.

Patients with pericardial closure of the auriclePatients without closure of the auricle

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients aged 18 years or older
  • Affiliation to a social security scheme
  • Non-valvular, paroxysmal, persistent or permanent atrial fibrillation
  • CHA2DS2-VASc greater than or equal to 2
  • History of intracranial haemorrhage: Intra-parenchymal hematoma, subacute or chronic subcutaneous hematoma And
  • Patients having benefited from the percutaneous closure of the auricle at the University Hospital of Amiens
  • Either patient admitted to the CHU of Amiens in neurology, neurosurgery or geriatrics for intracranial haemorrhage, who received standard medical treatment for the comparison group.

You may not qualify if:

  • CHADS2VASC2 less than 2
  • Extradural hematoma
  • Arachnoidal haemorrhage by rupture of aneurysm
  • Haemorrhagic transformation of ischemic stroke
  • Other indication of anticoagulation than FA
  • Modified Rankin scale greater than 4 following intracranial hemorrhage.
  • Early death, in the month following the onset of intracranial hemorrhage.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU Amiens Picardie

Amiens, Picardie, 80054, France

Location

MeSH Terms

Conditions

Atrial FibrillationIntracranial Hemorrhages

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesHemorrhage

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SCREENING
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 7, 2017

First Posted

April 13, 2017

Study Start

July 14, 2016

Primary Completion

October 19, 2017

Study Completion

October 19, 2017

Last Updated

November 19, 2025

Record last verified: 2025-11

Locations